Drug diffusion coatings, applications and methods

• US 20040058056A1
• Filed: 08/12/2003
• Published: 03/25/2004
• Est. Priority Date: 07/06/2001
• Status: Abandoned Application

• Current Assignee: Biosurface Engineering Technologies, Inc. (Ferring Holding SA)
• Original Assignee: Biosurface Engineering Technologies, Inc. (Ferring Holding SA)
• Inventors: Chen, Meng, Zamora, Paul O., Osaki, Shigemasa
• Application Number:
  US10/332,307
• Publication Number:
  US 20040058056A1
• Time in Patent Office: Days
• US Class Current: 427/2.1
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 29/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2205/04 implanted
• CPC Class Codes: C08L 83/04 Polysiloxanes

Abstract

Methods, coatings and coated medical devices are provided, wherein a plasma-deposited aliphatic polymerized hydrocyclosiloxane membrane is deposited as a diffusion control barrier for a drug deliver component consisting of one or more therapeutic agents coated on a surface or contained within a matrix, preferably a polymeric matrix, coated on a surface. The plasma-polymerized hydrocyclosiloxane membrane coats all or substantially all of the drug delivery component in contact or communication with the exterior surface, such that all or substantially all of any drug or therapeutic agent must diffuse across the membrane in order to be released.

Claims

1. A biocompatible coating composition for therapeutic agent diffusion in vivo comprising:

a layer comprising a therapeutic agent dispersed in a polymeric matrix; and

a membrane posited over the layer, the membrane formed from the plasma polymerization of hydrocyclosiloxane monomer of the general formula;

where R is an aliphatic group having 1 to about 5 carbon atoms and n is an integer from 2 to about 10, and

wherein the membrane cross-links with the polymeric matrix of the layer.

2. The coating composition of claim 1, wherein n is 7 to 10.

3. The coating composition of claim 1, wherein n is 4 to 6.

4. The coating composition of claim 1, wherein n is 2 to 3.

5. The coating composition of claim 1, wherein the hydrocyclosiloxane monomer is selected from the group consisting of 1,3,5,7-tetramethylhydrocyclotetrasiloxane, 1,3,5,7,9-pentamethylhydrocyclopentasiloxane, 1,3,5,7,9,11-hexamethylhydrocyclohexasiloxane, and a mixture of 1,3,5,7,9-pentamethylcyclopentasiloxane and 1,3,5,6,9,11-hexamethylcyclohexasiloxane monomers.

6. The coating composition of claim 1, wherein the polymer is selected from the group consisting of poly(2-hydroxyethyl methacrylate), polycaprolactone and cellulose acetate butyrate.

7. The coating composition of claim 1, wherein the membrane has a thickness of between about 10 nm and about 450 nm.

8. The coating composition of claim 7, wherein the membrane has a thickness of between about 20 and about 250 nm.

9. The coating composition of claim 1, wherein the polymeric matrix contains between about 0.01 mg and about 5.0 mg of therapeutic agent per cm².

10. The coating composition of claim 9, wherein the polymeric matrix contains between about 0.1 mg and about 0.5 mg of therapeutic agent per cm².

18. The coating composition of claim 1, wherein the layer comprising the therapeutic agent contains between about 0.01 mg and about 5.0 mg of therapeutic agent per cm².

19. The coating composition of claim 18, wherein the layer comprising the therapeutic agent contains between about 0.1 mg and about 0.5 mg of therapeutic agent per cm².

11. A biocompatible coating composition for therapeutic agent diffusion in vivo comprising:

a layer comprising a therapeutic agent; and

a membrane posited over the layer, the membrane formed from the plasma polymerization of hydrocyclosiloxane monomer of the general formula;

where R is an aliphatic group having 1 to about 5 carbon atoms and n is an integer from 2 to about 10, and

wherein the membrane cross-links with at least a portion of the therapeutic agent of the layer.

12. The coating composition of claim 11, wherein n is 7 to 10.

13. The coating composition of claim 11, wherein n is 4 to 6.

14. The coating composition of claim 11, wherein n is 2 to 3.

15. The coating composition of claim 11, wherein the hydrocyclosiloxane monomer is selected from the group consisting of 1,3,5,7-tetramethylhydrocyclotetrasiloxane, 1,3,5,7,9-pentamethylhydrocyclopentasiloxane, 1,3,5,7,9,1 1-hexamethylhydrocyclohexasiloxane, and a mixture of 1,3,5,7,9-pentamethylcyclopentasiloxane and 1,3,5,6,9,11-hexamethylcyclohexasiloxane monomers.

16. The coating composition of claim 11, wherein the membrane has a thickness of between about 10 nm and about 450 nm.

17. The coating composition of claim 16, wherein the membrane has a thickness of between about 20 and about 250 nm.

20. An implantable medical device comprising:

a structural component adapted for implantation in a patient, the structural component comprising at least one exterior surface;

a layer comprising a therapeutic agent posited over at least a portion of the at least one exterior surface; and

a membrane posited over the layer, the membrane formed from the plasma polymerization of hydrocyclosiloxane monomer of the general formula;

where R is an aliphatic group having 1 to about 5 carbon atoms and n is an integer from 2 to about 10.

21. The implantable medical device of claim 20, wherein the layer comprising a therapeutic agent further comprises a polymeric matrix, whereby the therapeutic agent is dispersed in the polymeric matrix and the membrane cross-links with the polymeric matrix.

22. The implantable medical device of claim 20, wherein n is 7 to 10.

23. The implantable medical device of claim 20, wherein n is 4 to 6.

24. The implantable medical device of claim 20, wherein n is 2 to 3.

25. The implantable medical device of claim 20, wherein the hydrocyclosiloxane monomer is selected from the group consisting of 1,3,5,7-tetramethylhydrocyclotetrasiloxane, 1,3,5,7,9-pentamethylhydrocyclopentasiloxane, 1,3,5,7,9,11-hexamethylhydrocyclohexasiloxane, and a mixture of 1,3,5,7,9-pentamethylcyclopentasiloxane and 1,3,5,6,9,11-hexamethylcyclohexasiloxane monomers.

26. The implantable medical device of claim 21, wherein the polymeric matrix comprises a polymer is selected from the group consisting of poly(2-hydroxyethyl methacrylate), polycaprolactone and cellulose acetate butyrate.

27. The implantable medical device of claim 20, wherein the membrane has a thickness of between about 10 nm and about 450 nm.

28. The implantable medical device of claim 20, wherein the membrane has a thickness of between about 20 and about 250 nm.

29. The implantable medical device of claim 20, wherein the layer comprising a therapeutic agent contains between about 0.01 mg and about 5.0 mg of therapeutic agent per cm².

30. The implantable medical device of claim 29, wherein the layer comprising a therapeutic agent contains between about 0.1 mg and about 0.5 mg of therapeutic agent per cm².

31. The implantable medical device of claim 20, wherein the structural component comprises a medical device selected from the group consisting of stents, catheters, shunts, grafts, artificial blood vessels, nerve-growth guides, artificial heart valves, joint prosthetics, pacemaker leads, cardiovascular grafts, bone replacements, orthopedic plates and attachments, wound healing devices, cartilage replacement devices and urinary tract replacement devices.

32. A method of applying a biocompatible coating composition to a structural component for therapeutic agent diffusion in vivo comprising:

providing a structural component adapted for introduction into a patient, the structural component comprising at least one exterior surface;

positing a layer comprising a therapeutic agent over at least a portion of the at least one exterior surface; and

plasma depositing a membrane over the layer comprising a therapeutic agent, the membrane formed from the plasma polymerization of hydrocyclosiloxane monomer of the general formula;

where R is an aliphatic group having 1 to about 5 carbon atoms and n is an integer from 2 to about 10.

33. The method of claim 32, wherein positing the layer comprising a therapeutic agent further comprises positing a layer comprising a polymeric matrix and the therapeutic agent.

34. The method of claim 32, wherein n is 7 to 10.

35. The method of claim 32, wherein n is 4 to 6.

36. The method of claim 32, wherein n is 2 to 3.

37. The method of claim 32, wherein the hydrocyclosiloxane monomer is selected from the group consisting of 1,3,5,7-tetramethylhydrocyclotetrasiloxane, 1,3,5,7,9-pentamethylhydrocyclopentasiloxane, 1,3,5,7,9,11-hexamethylhydrocyclohexasiloxane, and a mixture of 1,3,5,7,9-pentamethylcyclopentasiloxane and 1,3,5,6,9,11-hexamethylcyclohexasiloxane monomers.

38. The method of claim 33, wherein the polymeric matrix comprises a polymer is selected from the group consisting of poly(2-hydroxyethyl methacrylate), polycaprolactone and cellulose acetate butyrate.

39. The method of claim 32, wherein the membrane has a thickness of between about 10 nm and about 450 nm.

40. The method of claim 39, wherein the membrane has a thickness of between about 20 and about 250 nm.

41. The method of claim 32, wherein the layer comprising a therapeutic agent contains between about 0.01 mg and about 5.0 mg of therapeutic agent per cm².

42. The method of claim 41, wherein the layer comprising a therapeutic agent contains between about 0.1 mg and about 0.5 mg of therapeutic agent per cm².